|
Acquisitions (Narrative) (Details) (USD $)
|
3 Months Ended | 12 Months Ended | 0 Months Ended | 3 Months Ended | 0 Months Ended | 3 Months Ended | 0 Months Ended | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
Dec. 31, 2011
Arresto Biosciences, Inc. [Member]
|
Mar. 31, 2011
Arresto Biosciences, Inc. [Member]
|
Jan. 14, 2011
Arresto Biosciences, Inc. [Member]
|
Dec. 31, 2010
Arresto Biosciences, Inc. [Member]
|
Dec. 31, 2011
Calistoga Pharmaceuticals, Inc. [Member]
|
Apr. 02, 2011
Calistoga Pharmaceuticals, Inc. [Member]
|
Mar. 31, 2011
Calistoga Pharmaceuticals, Inc. [Member]
|
Feb. 28, 2011
Calistoga Pharmaceuticals, Inc. [Member]
|
Jan. 14, 2011
Calistoga Pharmaceuticals, Inc. [Member]
|
Jul. 08, 2010
CGI Pharmaceuticals, Inc. [Member]
|
Dec. 31, 2011
CGI Pharmaceuticals, Inc. [Member]
|
Jun. 30, 2010
CGI Pharmaceuticals, Inc. [Member]
|
Apr. 15, 2009
CV Therapeutics, Inc. [Member]
|
Mar. 31, 2011
CV Therapeutics, Inc. [Member]
|
Dec. 31, 2010
CV Therapeutics, Inc. [Member]
|
Apr. 15, 2009
Ranexa [Member]
|
Apr. 15, 2009
Lexiscan [Member]
|
Apr. 15, 2009
Marketed Products [Member]
CV Therapeutics, Inc. [Member]
|
Apr. 15, 2009
Intangible Assets - IPR&D [Member]
CV Therapeutics, Inc. [Member]
|
Apr. 15, 2009
2.75% Senior Subordinated Convertible Notes Due 2012 [Member]
CV Therapeutics, Inc. [Member]
|
Apr. 15, 2009
3.25% Senior Subordinated Convertible Notes due 2013
CV Therapeutics, Inc. [Member]
|
Apr. 15, 2009
2.0% Senior Subordinated Convertible Debentures Due 2023 [Member]
CV Therapeutics, Inc. [Member]
|
Apr. 15, 2009
GS-9667 [Member]
CV Therapeutics, Inc. [Member]
|
|
| Business Acquisition [Line Items] | ||||||||||||||||||||||||||||
| Total cash paid for acquisition | $ 221,700,000 | $ 373,700,000 | $ 91,000,000 | $ 1,380,000,000 | ||||||||||||||||||||||||
| Aggregate consideration transferred for the acquisition | 225,000,000 | 375,000,000 | 102,100,000 | 1,392,558,000 | ||||||||||||||||||||||||
| Acquisition-date fair value of total consideration transferred to acquire company | 227,100,000 | 484,300,000 | ||||||||||||||||||||||||||
| Contingent consideration paid | 5,400,000 | 110,600,000 | 11,100,000 | |||||||||||||||||||||||||
| Acquisition-date fair value of intangible assets | 117,000,000 | 149,200,000 | 2,900,000 | |||||||||||||||||||||||||
| Present value discount rate | 16.00% | 11.00% | 18.00% | |||||||||||||||||||||||||
| Goodwill resulting from acquisition | 134,482,000 | 134,482,000 | 336,951,000 | 336,951,000 | 70,111,000 | 341,910,000 | ||||||||||||||||||||||
| Potential payments based on the achievement of milestones | 225,000,000 | |||||||||||||||||||||||||||
| Maximum consideration of acquisition | 120,000,000 | |||||||||||||||||||||||||||
| Maximum value of contingent consideration | 29,000,000 | |||||||||||||||||||||||||||
| Fair value of intangible assets related to IPR&D | 138,900,000 | 93,400,000 | ||||||||||||||||||||||||||
| Intangible assets related to the marketed products | 688,400,000 | 262,800,000 | 951,200,000 | |||||||||||||||||||||||||
| Asset impairment charges | 26,600,000 | 136,000,000 | 26,630,000 | 136,000,000 | 0 | 26,600,000 | ||||||||||||||||||||||
| Indefinite-lived intangible assets | 266,200,000 | 29,530,000 | 266,200,000 | 29,530,000 | ||||||||||||||||||||||||
| Percentage of shares acquired on outstanding shares of common stock | 89.00% | |||||||||||||||||||||||||||
| Fair value of vested stock options | 15,700,000 | |||||||||||||||||||||||||||
| Business acquisition, equity interest issued or issuable, basis for determining value | In accordance with the merger agreement, the number of Gilead stock options and restricted stock units into which assumed CV Therapeutics' stock options and restricted stock units were converted was determined based on an option conversion ratio. This conversion ratio was calculated by taking the per share acquisition price of $20.00 and dividing it by the average closing price of our common stock for the five consecutive trading days immediately preceding (but not including) the closing date of April 17, 2009, which was $46.24 per share. The fair value of stock options assumed was calculated using a Black-Scholes valuation model with the following assumptions: market price of $44.54 per share, which was the closing price of our common stock on the acquisition date; expected term ranging from 0.1 to 5.2 years; risk-free interest rate ranging from 0.1% to 1.7%; expected volatility ranging from 37.4% to 43.2%; and no dividend yield. The fair value of restricted stock units assumed was calculated using the acquisition-date closing price of $44.54 per share for our common stock. |
|||||||||||||||||||||||||||
| Completed IPR&D project | 2,900,000 | |||||||||||||||||||||||||||
| Estimated fair value of unvested stock options and restricted stock units assumed | 11,200,000 | |||||||||||||||||||||||||||
| Deferred tax assets resulting from the acquisition primarily related to federal and state net operating loss and tax credit carryforwards | 413,816,000 | |||||||||||||||||||||||||||
| Deferred tax liabilities resulting from the acquisition primarily related to the difference between the book basis and tax basis of the intangible assets | 426,861,000 | |||||||||||||||||||||||||||
| Deferred tax liability reduced as result of impairment charges | 49,700,000 | |||||||||||||||||||||||||||
| Valuation allowance related to deferred tax assets | 9,209,000 | 13,040,000 | 9,209,000 | 13,040,000 | 15,100,000 | |||||||||||||||||||||||
| Senior Notes, stated interest rate | 2.75% | 3.25% | 2.00% | |||||||||||||||||||||||||
| Senior subordinated convertible notes - maturity date | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2023 | |||||||||||||||||||||||||
| Fair value of consideration transferred for business acquisition | $ 225,000,000 | $ 375,000,000 | $ 102,100,000 | $ 1,392,558,000 | ||||||||||||||||||||||||